Oncolytics shares rise on data from Reolysin study

SAN FRANCISCO (MarketWatch) -- Oncolytics Biotech Inc. /zigman2/quotes/204741333/composite ONCY -1.36% /zigman2/quotes/203812837/delayed CA:ONC 0.00% shares rose 10% to $2.15 in Tuesday morning trade. The company said researchers will present data Tuesday showing that treatment of human colon cancer cell lines with the combination of Reolysin and gemcitabine resulted in both in vitro and in vivo synergy. There was no toxicity associated with the combined treatment, and tumors treated with the combination were significantly smaller than tumors in control groups or tumors treated with either agent alone, the company said. Oncolytics said in a statement that "the researchers concluded that the synergistic combination of Reolysin and gemcitabine is a promising therapeutic regimen for study in clinical trials." Reolysin is the company's proprietary formulation of the human reovirus.

/zigman2/quotes/204741333/composite

Add to watchlist ONCY

Oncolytics Biotech Inc.

US : U.S.: Nasdaq

$ 2.18

-0.03 -1.36%

Volume: 202,510

Sept. 29, 2023 4:00p

P/E Ratio

N/A

Dividend Yield

N/A

Market Cap

$159.24 million

Rev. per Employee

N/A

/zigman2/quotes/203812837/delayed

Add to watchlist CA:ONC

Oncolytics Biotech Inc.

CA : Canada: Toronto

$ 2.97

0.00 0.00%

Volume: 40,236

Sept. 29, 2023 3:59p

P/E Ratio

N/A

Dividend Yield

N/A

Market Cap

$214.94 million

Rev. per Employee

N/A